Summary
Pfizer Inc. announced on February 8, 2016, a significant organizational change within its leadership structure. Geno Germano, Group President of the Global Innovative Pharma Business, is departing the company. This departure coincides with the ongoing pending transaction between Pfizer and Allergan plc. In response to Germano's departure and in anticipation of the Allergan merger, Pfizer is restructuring its business units. The Global Innovative Pharma business and the Vaccines, Oncology, and Consumer Healthcare business will operate independently under the leadership of Albert Bourla. Furthermore, the company provided a preview of the executive leadership team expected for the combined Pfizer-Allergan entity once the transaction is completed, signaling proactive planning for the integration.
Key Highlights
- 1Geno Germano, Group President of Global Innovative Pharma Business, is leaving Pfizer.
- 2Albert Bourla will lead Pfizer's Global Innovative Pharma business and its Vaccines, Oncology, and Consumer Healthcare business separately until the Allergan transaction closes.
- 3Pfizer announced the anticipated executive leadership team for the combined Pfizer-Allergan organization post-merger.
- 4The organizational changes are effective immediately and are linked to the pending acquisition of Allergan.
- 5This filing incorporates by reference a press release dated February 8, 2016, detailing these announcements.